Introduction {#Sec1}
============

Pompe disease (OMIM 232300: acid maltase deficiency or glycogen storage disease type II) is an inheritable lysosomal storage disorder caused by a deficiency of acid α-glucosidase that leads to glycogen accumulation in various body tissues, predominantly skeletal, cardiac and smooth muscle (Hirschhorn [@CR8]; van der Ploeg and Reuser [@CR26]). Patients with the classic-infantile form of the disease develop generalized hypotonia and a hypertrophic cardiomyopathy. Without treatment, these patients die in the first year of life due to cardiorespiratory failure (van den Hout et al [@CR24]). In the non-classic form of the disease, which can present at any age, progressive muscle weakness is the predominant symptom. In general, there is no significant cardiac involvement (Soliman et al [@CR21]; van der Beek et al [@CR25]).

Over the last two decades, several reports have hypothesized that glycogen accumulation in the smooth muscle tissue of arteries leads to vascular abnormalities in non-classic Pompe disease, such as cerebral aneurysms, basilar artery dolichoectasia, carotid dissection and dilated arteriopathy of the thoracic aorta (Braunsdorf [@CR2]; Winkel et al [@CR29], [@CR30]; Laforet et al [@CR13]; Sacconi et al [@CR20]; El-Gharbawy et al [@CR5]). The first indication of increased aortic stiffness in non-classic Pompe disease was reported in a study on 17 Pompe patients that used transthoracic Doppler echocardiography, a non-invasive tool that measures aortic stiffness indirectly (Nemes et al [@CR17]). The presence of increased aortic stiffness may be relevant, since it is considered to be an independent risk factor for cardiovascular disease and mortality (Mattace-Raso et al [@CR16]; Verbeke et al [@CR28]). The emerging gold standard for measuring it directly and non-invasively is tonometry of the carotid-femoral pulse wave velocity (cfPWV) (Van Bortel et al [@CR23]).

To determine whether increased arterial stiffness is a feature of non-classic Pompe disease, we used various techniques including tonometry of the cfPWV to investigate the structural and functional vascular properties of different vascular territories in a large group of patients with non-classic Pompe disease. We compared the results with those in age- and gender-matched volunteers.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

Between March 2012 and June 2013 we performed a cross-sectional single-centre case-controlled study in 84 patients with non-classic Pompe disease and 179 volunteers. All patients were 18 years or older. As the volunteers were matched for gender and age category, there were, per patient, at least two volunteers of the same gender and the same age category. The volunteers were either the patients' partners, or were employees or students of Erasmus University Medical Center, or otherwise visitors to it. Informed consent was obtained from all participants. The study protocol was approved by the Medical Ethical Committee at Erasmus University Medical Center

Cardiovascular risk factors {#Sec4}
---------------------------

All participants filled out a questionnaire to assess cardiovascular risk factors, which included gender, date of birth, length, weight, medication use, and comorbidities such as hypertension, diabetes mellitus, hypercholesterolemia and cardiovascular disease (i.e. transient ischemic attack, stroke, myocardial infarction or rhythm disturbances). Body mass index (BMI), which was calculated as body weight divided by height squared, was expressed as kg/m^2^. An automatic mercury cuff sphygmomanometer on the right arm was used to measure heart rate and blood pressure, including the mean arterial blood pressure (MAP), when the patient was in supine position after 5 min of rest in a quiet and heat-controlled room. Hypertension was defined as a systolic blood pressure (SBP) \> 140 mmHg and/or diastolic blood pressure (DBP) \> 90 mmHg (Mancia et al [@CR15]).

Vascular measurements {#Sec5}
---------------------

Aortic stiffness was measured using arterial tonometry from the right radial, right carotid and right femoral arteries using the SphygmoCor**®** device (Sphygmocor version 7.1, AtCor Medical, Sydney, Australia) according to previously described procedures (van Dijk et al [@CR27]). Transit distance was assessed on the basis of body surface measurement from the carotid artery to the femoral artery: 80 % of this distance was used as pulse-wave-travelled distance (Van Bortel et al [@CR23]). The primary outcome measure, cfPWV, was expressed in meters per second (m/s). The secondary and indirect outcome parameters for arterial stiffness measured with pulse wave analysis (PWA) of the right radial artery were central pulse pressure (PPc), augmentation index (AIx) and aortic reflexion time (ATr). PPc was calculated as the difference between aortic systolic and diastolic pressure; AIx was calculated from the aortic pressure waveform obtained by applying a general transfer function to the radial pressure waveform. For the comparison between two groups, AIx was normalized to a heart rate of 75 beats per minute. ATr was calculated as the time interval between the foot of the pressure wave and the shoulder of the reflected wave (Laurent et al [@CR14]; DeLoach and Townsend [@CR4]; Huijben et al [@CR10]).

The distensibility and IMT of the right common carotid artery were measured two centimetres below the carotid bifurcation using a vessel-wall movement-detector system (Art.Lab, Esaote Europe, Maastricht, the Netherlands) according to previously described procedures (van Dijk et al [@CR27]). The distensibility coefficient, a local measurement of carotid stiffness, was calculated as (2ΔD/D)/PP(10^−3^/kPa) (Hoeks et al [@CR9]), in which D is the diameter during diastole, ΔD is the measured distensibility (systolic diameter -- diastolic diameter), and PP is the aortic pulse pressure derived from radial applanation. Tonometry and ultrasonography were performed by two trained physicians (SW or EK).

Statistical analyses {#Sec6}
--------------------

Unless otherwise specified, data are presented as medians with interquartile ranges (IQR). Because cfPWV, PPc, AIx, ATr, distensibility and IMT were not normally distributed, the Mann--Whitney test was used to compare these outcomes between the total groups of patients and volunteers.

Linear regression analyses were used to study cfPWV separately. First, univariate regression analyses were performed. Next, the regression coefficients with a p-value less than 0.05 or variables that were considered clinically relevant were analysed in a multivariate regression model using bootstrap estimation. The final multivariate model contained age, gender, MAP, heart rate and diabetes mellitus.

We also performed a stratified analysis between patients and volunteers in three age groups: 20-39, 40-59 and 60+. To determine whether cfPWV was influenced by disease duration, treatment with ERT, and wheelchair or ventilator dependency, we also analysed cfPWV in separate multivariate regression models using bootstrap estimation. The final model for these analyses included four variables: age, gender, MAP and heart rate. The data were analysed using SPSS 20. A p-value of less than 0.05 was considered statistically significant.

Results {#Sec7}
=======

Study population {#Sec8}
----------------

Table [1](#Tab1){ref-type="table"} shows the characteristics of the two groups. In total, 84 patients with non-classic Pompe disease and 179 volunteers were included in the study. Twenty-six percent of the patients were wheelchair dependent, and 31 % needed artificial ventilation. Eighty-two percent of the patients were treated with ERT and the median duration of treatment was 5 years (IQR 4-5). CfPWV could not be measured in nine patients, either because they could not lie in supine position due to respiratory failure, or because their use of accessory muscles made it difficult to visualize the carotid artery. Neither could cfPWV be measured in the other eight volunteers due to temporary technical problems with the SphygmoCor® system.Table 1Demographic and clinical characteristicsPompe patientsVolunteersNumber of individuals84179Age in years54 (42-63)54 (41-61)Gender -- male (%)41 (49)85 (48)Body mass index in kg/m^2^24.7 (22.0-27.3)24.0 (22.2-26.0)Smoking status (%) ▪ Never36 (43)107 (60) ▪ Past41 (49)53 (29) ▪ Current7 (8)19 (11)Medical history ▪ Hypertension (%)30 (36)^a^35 (20) ▪ Diabetes mellitus (%)5 (6)6 (3) ▪ Hypercholesterolemia (%)8 (10)18 (10) ▪ Cardiovascular disease (%)7 (8)9 (5)Antihypertensive medication (%)23 (77)31 (89)Disease duration in years16 (12-23)-Patients receiving ERT (%)69 (82)-Duration of ERT in years5 (4-5)-Wheelchair use (%)22 (26)0 (0)Ventilator use (%)26 (31)0 (0)Continuous variables are given as medians with interquartile ranges (IQR), and categorical variables as numbers and percentages^a^In the past, more patients with Pompe disease than volunteers were diagnosed with hypertension (p-0.005)

Cardiovascular risk factors {#Sec9}
---------------------------

In the past, more patients with Pompe disease than volunteers had been diagnosed with hypertension (*p* = 0.005, Table [1](#Tab1){ref-type="table"}). Seventy-seven per cent of the Pompe patients with an earlier diagnosis of hypertension used antihypertensive medication at the time of evaluation, and 89 % in the group of volunteers. Despite treatment with antihypertensive medication, blood pressure continued to be high in 52 % of the Pompe patients who were treated for hypertension and in 65 % of the volunteers. As Table [2](#Tab2){ref-type="table"} shows, MAP was higher in patients than in volunteers (100 mmHg (IQR 90-111) versus 92 mmHg (IQR 84-103), *p* \< 0.001). Thirty-nine per cent of the patients met the criteria for hypertension (SBP \> 140 mmHg and/or DBP \> 90 mmHg), versus 20 % of the volunteers (*p* = 0.001). At group level, patients with Pompe disease had a higher heart rate (75 beats per minute (bpm) (IQR 68-83)) than the volunteers (65 bpm (IQR 59-71), *p* \< 0.001).Table 2Functional and structural hemodynamic parameters in patients and volunteersPompe patients (*n* = 84)Volunteers (*n* = 179)*P*-valueMean arterial pressure (mmHg)100 (90-111)92 (84-103)\<0.001Heart rate (beats per minute)75 (68-83)65 (59-71)\<0.001Diameter carotid artery (mm)6.6 (6.1-7.3)7.1 (6.5-7.8)\<0.001Intima media thickness (μm)582 (514-683)592 (506-695)0.68Distensibility coefficient (10^−3^/kPa)2.9 (1.9-4.1)2.7 (2.2-4.1)0.72Carotid-femoral pulse wave velocity (m/s)8.8 (7.1-10.7)7.4 (6.6-8.6)\<0.001Central pulse pressure (mmHg)38 (31-47)36 (31-43)0.30Augmentation index (%)21.7 (13.2-30.3)19.4 (8.5-29.4)0.23Aortic reflexion time (ms)140 (132-149)144 (135-159)0.02Continuous variables are given as medians with interquartile ranges (IQR). The diameter of the carotid artery was measured in 179 volunteers and 84 patients; IMT was measured in 179 volunteers and 83 patients; the distensibility coefficient was measured in 176 volunteers and 80 patients; cfPWV was measured in 171 volunteers and 79 patients; and PPc, Aix and ATr were measured in 178 volunteers and 83 patients

There were no differences in the occurrence of comorbidities such as diabetes mellitus or hypercholesterolemia. Seven patients with Pompe disease had a medical history of cardiovascular disease: four of them (three female) had had a transient ischemic attack between the ages of 48 and 62 years); two male patients had developed atrial fibrillation at the ages of 37 and 64 years; and one female patient had had a myocardial infarction at the age of 74 years. Nine volunteers had a medical history of cardiovascular disease. This was not statistically different from the seven Pompe patients (*p* = 0.30).

Aortic stiffness {#Sec10}
----------------

As shown in Table [2](#Tab2){ref-type="table"}, median cfPWV was 8.8 m/s in patients with Pompe disease (IQR 7.1-10.7) and 7.4 m/s in volunteers (IQR 6.6-8.6) (*p* \< 0.001). This difference was still present after adjustment for age, gender, MAP, heart rate and diabetes mellitus (*p* = 0.001). Subgroup analysis showed that while it occurred in the 40-59 years age group (8.6 m/s in patients versus 7.6 m/s in volunteers, *p* = 0.004) and the 60+ years (11.5 versus 9.3 m/s, *p* = 0.01), it did not occur in the 20-39 years age group (Fig. [1](#Fig1){ref-type="fig"}). PPc and AIx did not differ significantly between patients and volunteers, while ATr was shorter in patients than in volunteers (*p* = 0.02).Fig. 1Mean values of cfPWV in patients and volunteers per age category. The *boxplots* represent the mean values and 95 % CI of cfPWV per age category after adjustment for age, gender, mean arterial blood pressure, heart rate and diabetes mellitus. The number of patients and volunteers per age group are given in the *bars*

CfPWV did not differ between Pompe patients whose disease duration was shorter than 15 years (*n* = 35) and those whose disease duration was longer than 15 years (*n* = 44) (9.1 versus 9.4 m/s, *p* = 0.51). Neither did it differ between patients treated with ERT (*n* = 64) and treatment-naïve patients (*n* = 15) (9.4 versus 8.6 m/s, *p* = 0.17). Similarly, cfPWV did not differ between wheelchair-dependent patients (*n* = 12) and ambulant patients (*n* = 62) (9.4 versus 9.2 m/s, *p* = 0.75), or between ventilator-dependent patients (*n* = 18) and non-ventilated patients (*n* = 56) (9.6 versus 9.1 m/s, *p* = 0.42).

Carotid stiffness and IMT {#Sec11}
-------------------------

Table [2](#Tab2){ref-type="table"} shows that there were no significant differences in distensibility or IMT between patients and volunteers. The diameter of the carotid artery was smaller in patients than in volunteers (6.6 mm (IQR 6.1-7.3) versus 7.1 mm (IQR 6.5-7.8), *p* \< 0.001). Subgroup analysis showed that the distensibility was lower in patients with Pompe disease aged between 20 and 39 years than in volunteers (*p* = 0.03), but not in the other age-related subgroups.

Glycogen accumulation in vascular smooth muscle {#Sec12}
-----------------------------------------------

Figure [2](#Fig2){ref-type="fig"} shows the muscle biopsy of a 50-year-old male patient with Pompe disease who participated in this study and had no medical history of cardiovascular diseases. He developed the first symptoms at age 44, and now has severe limb-girdle weakness and decreased pulmonary function in sitting and supine positions. The biopsy was stained with periodic acid-Schiff (PAS) and shows glycogen storage in skeletal muscle fibres and in vascular smooth muscle fibres.Fig. 2Glycogen accumulation in vascular smooth muscle fibres. Muscle biopsies of adult patients with non-classic Pompe disease stained with periodic acid-Schiff (PAS) to demonstrate glycogen storage in vascular smooth muscle fibres (*black arrowheads*). Original magnification: 630×

Discussion {#Sec13}
==========

We found that patients with the non-classic form of Pompe disease have increased aortic stiffness and blood pressure. These findings indicate clinical relevant involvement of the cardiovascular musculature in this group of Pompe patients.

Glycogen accumulation in smooth muscle fibres and in the endothelial layer of arteries has been shown in morphological studies and autopsy reports of patients with Pompe disease (Winkel et al [@CR29]; Thurberg et al [@CR22]; Kobayashi et al [@CR12]). Figure [2](#Fig2){ref-type="fig"} shows glycogen storage in vascular smooth muscle fibres in one of our adult patients with Pompe disease before the start of ERT. While it is likely that the increased glycogen storage in smooth muscle fibres results in an increased arterial stiffness, it is also possible that glycogen accumulation in the endothelium damages the vascular wall, making it more vulnerable to atherosclerosis; in the presence of other cardiovascular risk factors, this process might increase arterial stiffness. As vascular stiffness has also been described as depending on the distribution of collagen and elastin, an increase in abnormal collagen and a decrease in normal elastin contributes to greater arterial stiffness (Laurent et al [@CR14]). During the course of the disease, patients with Pompe disease may develop striated muscle atrophy with some increase in connective tissue. If this process also occurred in the vascular smooth muscle fibres of Pompe patients, it would help to explain increased aortic stiffness.

Increased aortic stiffness has also been described in other lysosomal storage disorders such as Fabry disease and mucopolysaccharidosis type I (MPS I or Scheie syndrome). In Fabry disease, storage of glycosphingolipids takes place in vascular endothelial and smooth muscle cells, and in MPS I, accumulation of glycosaminoglycans in the connective tissue of the aortic wall impairs the formation of elastin and leads to changes in collagen formation (Nemes et al [@CR18]; Collin et al [@CR3]). It has been shown in Fabry disease that ERT can normalize aortic stiffness (Collin et al [@CR3]). As most of the patients with Pompe disease enrolled in our cross-sectional study were treated with ERT, the difference in cfPWV between patients and volunteers might have been even more pronounced if it had been measured before the start of ERT. It would thus be interesting to establish whether aortic stiffness in Pompe patients decreases during ERT, and whether cfPWV can be used as a non-invasive tissue biomarker for disease progression and therapy response.

To the best of our knowledge, this is the first study to show that arterial blood pressure is increased in patients with Pompe disease. It is reasonable to assume that any structural changes in the blood vessels caused by the increased aortic stiffness would lead to higher blood pressure. Increased aortic stiffness and hypertension are both independent risk factors for cardiovascular disease and mortality (Mattace-Raso et al [@CR16]; Verbeke et al [@CR28]). It has been shown that patients with non-classic Pompe disease have improved survival when treated with ERT (Güngör et al [@CR7]). Since cardiovascular diseases are more common at a higher age, Pompe patients will be more likely to develop cardiovascular diseases, as they owe their higher age to ERT. In these patients it is therefore important to closely monitor risk factors for cardiovascular diseases such as hypertension, hypercholesterolemia, diabetes mellitus and smoking, and to treat them when indicated. Although exercise and training, dietary changes and pharmacological treatments have sometimes been shown to reduce arterial stiffness in healthy individuals and other patient groups (Kingwell et al [@CR11]; Girerd et al [@CR6]; Balkestein et al [@CR1]), it has not yet been investigated whether they are also beneficial in Pompe patients.

Although we expected Pompe disease to have a similar effect on the vascular structure of all arteries, and thereby to increase cfPWV and reduce distensibility, we found changes in carotid distensibility only in patients aged between 20 and 39 years. In those with high blood pressure and diabetes it has been reported that the aorta stiffened more than the carotid artery with age and with other cardiovascular risk factors such as increased body mass index and heart rate (Paini et al [@CR19]). These findings may have been paralleled by our own finding in most of the Pompe patients whose blood pressure and heart rate were increased, who also had greater aortic stiffness without decreased distensibility.

A strength of our study is that we used cfPWV, which is currently the gold standard for measuring aortic stiffness directly and non-invasively in a relatively large group of Pompe patients. A previous study that found increased aortic stiffness in a small group of patients with Pompe disease used transthoracic echocardiography, an indirect way of measuring aortic stiffness (Nemes et al [@CR17]).

Our study has some limitations. First, due to physical or temporary technical problems, measurements of aortic stiffness were not available for all subjects. However, as most of the patient data that were missing in the group of Pompe patients were those for the elderly and more severely affected patients, this would probably have led to an underestimation of the real difference in aortic stiffness between Pompe patients and healthy volunteers. Second, as this was a cross-sectional study, we do not know about the progression of aortic stiffness over time, or about the effects of ERT on aortic stiffness. Additionally, rather than measuring glucose or cholesterol in blood samples, we used a questionnaire to establish whether patients had a history of hypercholesterolemia or diabetes mellitus.

In conclusion, patients with non-classic Pompe disease have increased aortic stiffness and blood pressure. To reduce the potential risk of cardiovascular diseases, we recommend that blood pressure and other common cardiovascular risk factors are monitored closely. Prospective studies should investigate whether ERT reduces aortic stiffness, or whether early treatment even prevents it.
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